Angiotensin II Receptor Blockade in Vascular Ehlers Danlos Syndrome (ARCADE)

Ehlers-Danlos Syndrome, Vascular Type Clinical Trial

— ARCADE  

Official title:

Angiotensin II Receptor Blockade in Vascular Ehlers Danlos Syndrome: a Double Blind, Randomized, Placebo Controlled, Multicenter Trial.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02597361
• Other study ID #: P140918
• Secondary ID: 2015-001065-76
• Status: Completed
• Phase: Phase 3
• Start date: January 2016
• Est. completion date: February 19, 2020

Study information

• Verified date: October 2020
• Source: Assistance Publique - Hôpitaux de Paris
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study aims to verify the hypothesis that patients with Vascular Ehlers Danlos syndrome (vEDS) should benefit of the blockade of angiotensin (Ang) II noxious effects on their vasculature affected by a defect in type III collagen in addition to the effects celiprolol. This randomized, double blind, placebo controlled trial compares the administration of the Ang II type I receptor blocker (ARB) - irbesartan- to placebo over a 2-year period in vEDS patients with the main objective to reduce the incidence of both symptomatic and asymptomatic vascular events.

Description:

vEDS is a rare life-threatening inherited condition due to mutations at the COL3A1 gene encoding the pro-alpha 1 chain of type III procollagen (OMIM #130050) with unpredictable and recurring arterial dissections/aneurysms starting in the early adulthood. The investigators have previously shown that a treatment with 200-400 mg per day of celiprolol, reduces both fatal and non-fatal vascular events in patients with vEDS. If tolerated, the treatment is now the standard treatment for vEDS. However, despite celiprolol , symptomatic and asymptomatic arterial events continue to occur in vEDS patients. Recent findings suggest a possible deleterious effect of endogenous Angiotensin II on medium size arteries in vEDS patients. The hypothesis of this study is that the blockade of endogenous Ang II will provide supplemental vascular protection and thus reduce recurrence of arterial events in vEDS patients.

The primary objective of this study is to determine in patients with molecularly proven vEDS, whether an Ang II receptor blocker, prescribed at an optimally tolerated dose combined with the reference celiprolol treatment, decreases the 24 months rate of both asymptomatic and symptomatic cardiovascular (CV) events when compared to placebo.

Methodology:

Multicenter, double-blind, randomized (1:1), placebo-controlled, parallel group, study with blind endpoint evaluation in adult vEDS patients.

Main criteria for inclusion:

Patients of both sexes aged 18 to 70 years with molecularly proven vEDS, not in an acute phase of the disease, with no contra-indication for taking an Ang II blocker.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 61
• Est. completion date: February 19, 2020
• Est. primary completion date: February 19, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Patients with genetically-proven vEDS (presence of a pathogenic mutation at the COL3A1 gene);

• Age =18 years and <70 years;

• Men and women with reliable contraception or negative beta-HCG at screening;

• Celiprolol at the optimal tolerated dose since at least 12 weeks;

• vEDS patient fully intolerant to celiprolol but not treated with any other drug active on the vascular system, except another beta-blocker;

• No compelling indication for ARB therapy (renal infarction, hypertension, proteinuric nephropathy, chronic heart failure, myocardial infarction, stroke);

• Estimated glomerular filtration rate (GFR) = 30ml/min/1,73m2 (MDRD Formula);

• Normal or clinically acceptable 12-lead ECG;

• Written informed consent to participate in the study.

Exclusion Criteria:

General criteria

• Unlikely to co-operate in the study and/or poor compliance anticipated by the investigator, e.g., uncooperative attitude, inability to return for follow-up visit, and unlikelihood of completing the study;

• Participation in another interventional therapeutic study at the same time or within 3 months prior to the beginning of the present study;

• Participant not affiliated to the French social security;

• No written informed consent;

• Severe contrast media allergy, not amenable to pre-treatment Medical and therapeutic criteria

• History of previous symptomatic visceral complication (any CV event, pulmonary or digestive event) in the 3 months preceding the inclusion;

• Formal indication for an antihypertensive medication (office BP =140/90 mmHg on celiprolol on at least two separated visits, confirmed by daytime ambulatory BP or home BP = 135/85 mmHg);

• Concomitant treatment with renin-angiotensin-aldosterone system blocking agents apart from the study drug, e.g. ACEI, ARB or aldosterone-antagonist or any renin inhibitor, if given for an elective indication (heart failure, renal infarction, chronic kidney disease, proteinuria, myocardial infarction, stroke);

• Any cardiac condition that justifies a specific medical care (i.e. second or third degree auriculo-ventricular block, potentially life threatening arrhythmia or other uncontrolled arrhythmia or persistent arrhythmia, clinically significant valvular heart disease);

• Known significant renal artery stenosis with evidence of renal ischemia (on Duplex ultrasound, CTA, or other exam);

• Any concurrent life threatening condition other than vEDS with a life expectancy less than 2 years;

• Likely allergy or hypersensitivity to irbesartan, based on known allergies to drugs of the same class, or which in the opinion of the investigator suggests an increased potential for an adverse hypersensitivity as well as known or suspected contraindications to the study drug;

• Any condition that in the opinion of the investigator would jeopardize the evaluation of efficacy or safety;

• Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive Human Chorionic Gonadotropin (hCG) laboratory test (>5 mIU/ml);

• Women of child-bearing potential (WOCBP) without reliable contraception.

Related Conditions & MeSH terms

• Ehlers-Danlos Syndrome
• Ehlers-Danlos Syndrome, Vascular Type
• Syndrome

Intervention

Drug:
• Irbesartan
Irbesartan: 150 or 300 mg o.d. The up-titration of irbesartan from 150 mg to 300 mg o.d. occur during the first 8 weeks following randomization
• Placebo
Placebo o.d. to match 150mg or 300mg irbesartan tablets

Locations

Country	Name	City	State
France	CHU DE BORDEAUX - Hopital Saint Andre	Bordeaux
France	CHU DE LYON - Hopital Femme Mere Enfant	Bron
France	CHU DE CAEN - Hopital Cote de Nacre	Caen
France	CHU DE TOURS - Hopital Trousseau	Chambray-les-Tours
France	CHU DE GRENOBLE - Hopital Albert Michallon	Grenoble
France	CHU DE GRENOBLE - Hopital Couple Enfant	Grenoble
France	CHRU DE LILLE - Hopital Claude Huriez	Lille
France	CHU DE LYON - Hopital Edouard Herriot	Lyon
France	AP-HM - Hopital de la Timone	Marseille
France	CHU DE MONTPELLIER - Hopital Saint Eloi	Montpellier
France	CHU DE NANTES - Hopital Hotel-Dieu	Nantes
France	AP-HP - Hopital Europeen Georges-Pompidou	Paris
France	CHU DE TOULOUSE - Hopital Purpan	Toulouse
France	CHU DE TOULOUSE - Hopital Rangueil	Toulouse
France	CHRU DE NANCY - Institut Lorrain du Coeur et des Vaisseaux	Vandoeuvre-les-Nancy

Sponsors (2)

Lead Sponsor	Collaborator
Assistance Publique - Hôpitaux de Paris	Ministry of Health, France

Country where clinical trial is conducted

France, 

References & Publications (3)

Faugeroux J, Nematalla H, Li W, Clement M, Robidel E, Frank M, Curis E, Ait-Oufella H, Caligiuri G, Nicoletti A, Hagege A, Messas E, Bruneval P, Jeunemaitre X, Bergaya S. Angiotensin II promotes thoracic aortic dissections and ruptures in Col3a1 haploinsu — View Citation

Frank M, Albuisson J, Ranque B, Golmard L, Mazzella JM, Bal-Theoleyre L, Fauret AL, Mirault T, Denarie N, Mousseaux E, Boutouyrie P, Fiessinger JN, Emmerich J, Messas E, Jeunemaitre X. The type of variants at the COL3A1 gene associates with the phenotype and severity of vascular Ehlers-Danlos syndrome. Eur J Hum Genet. 2015 Dec;23(12):1657-64. doi: 10.1038/ejhg.2015.32. Epub 2015 Mar 11. — View Citation

Ong KT, Perdu J, De Backer J, Bozec E, Collignon P, Emmerich J, Fauret AL, Fiessinger JN, Germain DP, Georgesco G, Hulot JS, De Paepe A, Plauchu H, Jeunemaitre X, Laurent S, Boutouyrie P. Effect of celiprolol on prevention of cardiovascular events in vasc — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cardiovascular morbidity and mortality	Total number of any non-fatal and fatal cardiovascular events or events related to vEDS	2 years
Primary	Arterial lesions	number and severity of arterial lesions detected by CTA	2 years
Secondary	Rate of any symptomatic cardiovascular event	CV death; any morbid and fatal events related to vEDS; Any non fatal CV event; Non-fatal stroke	2 years
Secondary	Occurrence of new asymptomatic arterial lesions (aneurysm, dissection), detected by a systematic CTA	Arterial dissection/rupture/aneurysm in any vascular bed	2 years
Secondary	Time to first symptomatic clinical morbid and fatal events		2 years
Secondary	Number of unplanned hospitalization for any vEDS related event		2 years
Secondary	Total number of arterial lesions detected by vascular DUS	Echo duplex ultrasound made at inclusion, 6, 12, 18 and 24 months	2 years
Secondary	Total number of arterial lesions worsened during follow-up		2 years
Secondary	Changes in PWV (Pulse Wave Velocity)	Applanation tonometry made at randomization visit, 6, 12, 18 and 24 months	2 years
Secondary	Changes in large arteries properties (diameter, wall stress, stiffness)	Echotracking made at randomization visit, 6, 12, 18 and 24 months	2 years
Secondary	Decrease in office systolic/diastolic BP	Vital signs (BP and HR) measured by automatic device at each visit	2 years
Secondary	Change in estimated glomerular filtration rate (MDRD)	eGFR evaluated at each visit	2 years
Secondary	Tolerability and safety of the irbesartan assessed by orthostatic hypotension, plasma creatinine, plasma K+ evaluated at each visit		2 years
Secondary	Compliance to treatment	Spot urine for drug determination (celiprolol and irbesartan urinary detection) made at randomization visit and 3, 12 and 24 months	2 years
Secondary	Quality of life	SF36 and HADS questionnaires submitted to participants at randomization visit, 6, 12 and 24 months	2 years